Compare CLMT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | ANIP |
|---|---|---|
| Founded | 1916 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2024 | 1999 |
| Metric | CLMT | ANIP |
|---|---|---|
| Price | $26.72 | $73.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $21.25 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 1.3M | 285.9K |
| Earning Date | 03-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 0.04 | ★ 3.32 |
| Revenue | ★ $4,189,400,000.00 | $206,547,000.00 |
| Revenue This Year | $1.18 | $44.10 |
| Revenue Next Year | $2.45 | $13.18 |
| P/E Ratio | $753.75 | ★ $35.93 |
| Revenue Growth | 0.20 | ★ 2.47 |
| 52 Week Low | $7.68 | $56.71 |
| 52 Week High | $30.35 | $99.50 |
| Indicator | CLMT | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 35.37 |
| Support Level | $17.70 | $62.89 |
| Resistance Level | $29.92 | $85.12 |
| Average True Range (ATR) | 1.27 | 2.78 |
| MACD | -0.07 | -0.30 |
| Stochastic Oscillator | 32.53 | 12.37 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.